Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2-FDCK or Codeine or Methimazole (thiamazole)

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (2) · (multiple, generic dominant) (1) · Tapazole; outside US Mercazole (1)
classes:
Analgesic (2) · Dissociative (1) · Opioid (2) · Prodrug (1) · Research material (1) · [[:Category:Antithyroid_agents|Antithyroid agent]] (1) · [[:Category:Thionamides|Thionamide]] (1)
mechanism:
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · NMDA antagonist; fluorinated ketamine analogue (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-00000ECD-QINU`"' Agranulocytosis is the most-feared adverse effect (~0.3%, usually first 90 days of treatment; warn patients to seek urgent CBC for fever or severe sore throat). Hepatotoxicity is class-recognized but more often associated with PTU'"`UNIQ--ref-00000ECE-QINU`"'. (1)
uses:
None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000ECF-QINU`"', '"`UNIQ--vote-00000ED0-QINU`"', '"`UNIQ--vote-00000ED1-QINU`"', '"`UNIQ--vote-00000ED2-QINU`"' (1)
starting dose:
None (2) · 10-40 mg PO daily depending on hyperthyroidism severity; titrate by clinical and biochemical response (target TSH/free T4) (1) · Adult: 15–60 mg every 4 hours as needed. (1)
preparations:
None (2) · 5, 10 mg tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (2) · 360 mg/day (1) · 60 mg/d typical (1)
routes:
None (2) · Oral (1) · PO (only formulation marketed in the US). (1)
onset:
None (2) · 30–60 min (PO) (1) · Biochemical improvement within 2-4 weeks; full euthyroid state 6-12 weeks (1)
duration:
None (2) · 24 hours (1) · 4–6 hours (1)
halflife:
None (2) · 2.5–3 hours (1) · ~4-6 hours (plasma); intrathyroidal accumulation gives a much longer functional duration'"`UNIQ--ref-00000ED3-QINU`"' (1)
bioavailability:
None (2) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~93% (oral)'"`UNIQ--ref-00000ED4-QINU`"' (1)
pregnancy:
None (3) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)
legal:
None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 4 results in range #1 to #4.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"